Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4501 X St
2nd Floor
Sacramento, CA 95817Phone+1 916-734-5959Fax+1 916-703-5265
Summary
- Dr. Edward Kim is a medical oncology physician scientist at the UC Davis Comprehensive Cancer Center where he specializes in gastrointestinal malignancies. He graduated from Harvard University and received his MD/PhD from Stony Brook University School of Medicine and has been in practice 12 years.
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 2007 - 2011
- University of MichiganResidency, Internal Medicine, 2005 - 2007
- Stony Brook University Health Sciences Center School of MedicineClass of 2005
- Harvard UniversityAB, Chemistry, Magna cum laude, 1993 - 1997
Certifications & Licensure
- CA State Medical License 2012 - 2026
- MI State Medical License 2005 - 2015
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
- RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) Start of enrollment: 2016 Aug 30
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer Start of enrollment: 2018 Oct 16
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsNCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha
British Journal of Cancer. 2024-02-01 - 2 citationsPhase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma.Jasmine C Huynh, May Cho, Arta Monjazeb, Ebaa Al-Obeidi, Amisha Singh
Investigational New Drugs. 2024-02-01 - 17 citationsSotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial.Yasutoshi Kuboki, Marwan Fakih, John Strickler, Rona Yaeger, Toshiki Masuishi
Nature Medicine. 2024-01-01
Press Mentions
- $3 Million National Grant to Fund Pancreatic Cancer StudyFebruary 7th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: